AdvaMedDx Commends Increased Investment in Precision Medicine

You are here

AdvaMedDx Commends Increased Investment in Precision Medicine

January 30, 2015

Andrew Fish, executive director of AdvaMedDx, issued the following statement today in response to President Barack Obama’s newly announced Precision Medicine Initiative:

“We appreciate the Administration’s support for increased investments in precision medicine. Innovations in diagnostic tests, including genetic sequencing technologies, are a cornerstone of precision medicine. Diagnostic tests are the key to ensuring the right treatment for the right patient at the right time. AdvaMedDx member companies are the innovators whose technologies are providing incredible insights and revolutionizing health care. We look forward to working with the White House, NIH, FDA, and Congress on this important initiative.”

For more information, please contact: Wanda Moebius @ (202) 434-7240